外周血中芳香烃受体及芳香烃代谢酶活性与乳腺癌关系的研究

doi:10.3969/j.issn.1007-3969.2014.07.006

中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (7): 512-516.doi: 10.3969/j.issn.1007-3969.2014.07.006

外周血中芳香烃受体及芳香烃代谢酶活性与乳腺癌关系的研究

王天航¹,鲁英¹,杨晓燕¹,欧江华²

1.新疆医科大学公共卫生学院，新疆乌鲁木齐 833000；
2.新疆医科大学附属肿瘤医院乳腺外科，新疆乌鲁木齐 833000

出版日期:2014-07-30 发布日期:2014-07-29
通信作者: 杨晓燕　E-mail:390068143@qq.com
基金资助:
国家自然科学基金资助项目(No: 81160337)；新疆青年教师科研培训项目(No: XJEDU2011S23)

A study on the relationship of the activity of aryl hydrocarbon receptor and aryl hydrocarbon metabolic enzymes in peripheral blood and breast cancer

WANG Tian-hang¹,LU Ying¹,YANG Xiao-yan¹,OU Jiang-hua²

1.The Public Health College of Xinjiang Medical University, Urumqi Xinjiang 833000,China;
2. Department of Breast Surgery, Affiliated Cancer Hospital of XinJiang Medical University, Urumqi Xinjiang 833000, China

Published:2014-07-30 Online:2014-07-29
Contact: YANG Xiao-yan E-mail: 390068143@qq.com

摘要/Abstract

摘要：

背景与目的：大量研究表明，活化的芳香烃受体(aryl hydrocarbon receptor，AhR)可能参与了由多环芳烃诱导的乳腺癌的发生，AhR作为公认的配体激活的转录因子，可诱导多种酶表达。本研究旨在探讨芳香烃受体和芳香烃代谢酶在人体内蛋白水平与乳腺癌及其病理指标间的关系。方法：以1∶1配对进行病例对照研究，共收集65对血样，采用酶联免疫吸附法检测血液中芳香烃受体及芳香烃代谢酶蛋白水平，同时收集病理资料。计量资料使用秩和检验进行统计分析，相关性分析使用Spearman检验。结果：秩和检验发现对照组与病例组间醛脱氢酶(aldehyde dehydrogenase，ALDH)、细胞色素(cytochrome P450，CYP450)差异无统计学意义(Z=0.196，P=0.845；Z=0.269，P=0.788)；AhR、醌氧化还原酶(quinone oxido-ereductase 1，NQO1)、谷胱甘肽-S-转移酶(glutatnione-S-transferases，GST)对照组平均浓度低于病例组，差异有统计学意义(Z=1.956，P=0.041；Z=2.627，P=0.009；Z=3.272，P=0.001)。相关性分析结果显示，病例组中AhR与GST和NQO1相关性较高(r=0.665，P<0.01；r=0.704，P<0.01)。以病理指标(ER、PR、HER-2)-、+、++、+++分组，发现以雌激素受体ER分组的AhR、GST蛋白表达水平差异有统计学意义(P<0.05)。结论：实验结果显示芳香烃受体及芳香烃代谢酶蛋白水平对乳腺癌发生可能有重要影响，检测酶蛋白水平可能对乳腺癌的早期发现有帮助，对治疗方案的选择及预后有一定意义。

关键词: 乳腺癌, 芳香烃受体, 血清蛋白质浓度

Abstract:

Background and purpose: Previous studies showed activated aryl hydrocarbon receptor (AhR) might be involved in the development of breast cancer induced by polycyclic aromatic hydrocarbons (PHAs) and AhR which was regarded as transcription factors activated by ligand could induced many enzymes expression. Therefore, this study aimed to explore the protein level of AhR and aryl hydrocarbon metabolic enzymes in vivo with a relationship of the breast cancer and pathology indicators. Methods: A case-control study was 1∶1 matched and 65 pairs blood samples were collected, the ELISA was used in testing blood protein levels of the aromatic hydrocarbon receptor and aryl hydrocarbon metabolic enzymes. Meanwhile pathological data was collected. The Rank sum test statistical analysis was used in analyzing measurement data, Spearman test was used in correlation analysis. Results: Statistical analysis revealed that there was no statistical difference in aldehyde dehydrogenase(ALDH), cytochrome P450(CYP450) between the case group and the control group (Z=0.196,P=0.845;Z=0.269,P=0.788);and the AhR, NQO1, GST control group concentrations were lower than that in the case group. There were statistical differences of AhR, quinone oxido-ereductase 1(NQO1), glutatnione-S-transferases(GST) between the control group and the case group(Z=1.956, P=0.041; Z=2.627, P=0.009; Z=3.272, P=0.001). Correlation analysis showed that AhR has a higher correlation in case group with GST, NQO1 (r=0.665, P<0.01; r=0.704, P<0.01). Grouping with the pathology indicators (ER, PR, HER-2) -,+,++,+++, found that the level of grouping by ER, AhR protein levels and GST protein levels have a discrepancies(P<0.05). Conclusion: These results might suggest that the protein levels of AhR and aryl hydrocarbon metabolic enzymes have a significant impact on breast cancer. Detection of enzyme protein levels may be helpful for early detection of breast cancer, prompt treatment options and prognosis are meaningful.

Key words: Breast cancer, Aryl hydrocarbon receptor, Plasma protein concentration

王天航,鲁英,杨晓燕,欧江华. 外周血中芳香烃受体及芳香烃代谢酶活性与乳腺癌关系的研究[J]. 中国癌症杂志, 2014, 24(7): 512-516.

WANG Tian-hang,LU Ying,YANG Xiao-yan,OU Jiang-hua. A study on the relationship of the activity of aryl hydrocarbon receptor and aryl hydrocarbon metabolic enzymes in peripheral blood and breast cancer[J]. China Oncology, 2014, 24(7): 512-516.

[1]	章箎, 陈佳慧, 林瑾仪, 王妍, 张斯加, 朱玮, 程蕾蕾. 一种新型《乳腺癌治疗相关心血管毒性临床评分表》的价值分析[J]. 中国癌症杂志, 2022, 32(1): 54-60.
[2]	金奕滋, 林明曦, 张剑. DNA损伤应答缺陷作为乳腺癌治疗靶点的研究进展[J]. 中国癌症杂志, 2022, 32(1): 61-67.
[3]	《中国乳腺癌新辅助治疗专家共识（2022年版）》专家组. 中国乳腺癌新辅助治疗专家共识（2022年版）[J]. 中国癌症杂志, 2022, 32(1): 80-89.
[4]	张小艳, 李清祥, 刘　勇, 李　航, 仇丽娟, 封欣然, 谭立明 . HMGB1与乳腺癌患者临床病理学特征及免疫指标的相关性研究[J]. 中国癌症杂志, 2021, 31(9): 783-788.
[5]	曹爱玲, 曹　喆, 周　剑. 多西他赛联合胸腺肽α1对大鼠乳腺癌免疫微环境中Treg数量的影响及其机制研究[J]. 中国癌症杂志, 2021, 31(9): 799-806.
[6]	姚　嘉, 李冠乔, 杨时平, 苏慧銮 . Hsa-miR-98-5p/DKK3信号轴对乳腺癌细胞生物学行为的影响[J]. 中国癌症杂志, 2021, 31(9): 807-816.
[7]	丛斌斌, 王永胜. 激素受体阳性早期乳腺癌治疗现状与挑战[J]. 中国癌症杂志, 2021, 31(8): 689-696.
[8]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[9]	丁高峰, 郭雷鸣, 陆寓非. 乳腺癌患者HER2和BRCA1表达与放疗敏感性的关系研究[J]. 中国癌症杂志, 2021, 31(7): 589-595.
[10]	金优萍, 李录英, 周　平. 长链非编码RNA STMN1P2在乳腺癌中的作用及机制研究[J]. 中国癌症杂志, 2021, 31(7): 596-604.
[11]	谢金芳, 曹春雨, 任　雪, 田家俊, 吕亚丰, 黄晓飞 . 萝卜硫素对小鼠乳腺癌4T1细胞上皮-间质转化、增殖和迁移的影响研究[J]. 中国癌症杂志, 2021, 31(7): 605-615.
[12]	曾　峰, 李　丹, 邵鑫鑫, 张能英, 陈星翰, 程晓明 . 基于SEER数据库构建1~2枚淋巴结阳性且乳房全切的老年早期乳腺癌患者不同腋窝手术方式的生存预测模型[J]. 中国癌症杂志, 2021, 31(4): 323-329.
[13]	王春建 , 聂　刚 , 毛　艳 . TRIP6在乳腺癌中的作用及其机制研究[J]. 中国癌症杂志, 2021, 31(3): 161-169.
[14]	胡喜娥, 杨振宇, 薛景毅, 杨　平, 彭书甲, 袁利娟, 包国强 . 单细胞测序在三阴性乳腺癌新辅助化疗中的应用研究进展[J]. 中国癌症杂志, 2021, 31(3): 221-226.
[15]	侯　净, 程纪淦, 王　华, 魏　娜, 倪　青. 硝呋齐特增加乳腺癌细胞对奥拉帕利敏感性的初步研究[J]. 中国癌症杂志, 2021, 31(12): 1168-1173.

外周血中芳香烃受体及芳香烃代谢酶活性与乳腺癌关系的研究

A study on the relationship of the activity of aryl hydrocarbon receptor and aryl hydrocarbon metabolic enzymes in peripheral blood and breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价